Vimian’s Interim Report for the third quarter of 2026

• Revenue increased by 15 per cent to EUR 120.3m (104.3) with organic growth of 11 per cent
• Adjusted EBITA increased 14 per cent to EUR 29.2m (25.5) corresponding to a margin of 24.3 per cent (24.5)
• Operating profit (EBIT) of EUR 20.5m (17.5)
• Profit for the period of EUR 9.3m (6.8) and earnings per share before and after dilution EUR 0.02 (0.01)
• Cash flow from operating activities of EUR 22.6m (10.8)

”Vimian delivered another quarter with double-digit organic revenue growth and strong earnings growth. Total revenues grew 15 per cent to EUR 120.3 million with organic growth of 11 per cent. Our business continues to outperform the overall animal health market, reflecting the strength of our strategy with focus on attractive market niches, a strong brand portfolio and disciplined execution of our teams in an entrepreneurial organisation”, says Alireza Tajbakhsh, CEO Vimian, and continues:

“Adjusted EBITA grew 14 per cent to EUR 29.2 million at a margin of 24.3 per cent. We delivered strong earnings growth in all four segments, and after the end of the quarter we signed the acquisition of Norfolk Medical Products, expanding our offering into specialised soft tissue surgery.”

A telephone and webcast will be held for investors, analysts, and media, today at 09.00 (CET). The conference will be held in English and include a question-and-answer session.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://events.inderes.com/vimian-group/q3-report-2026/dial-in

To attend the webcast:
Link: https://events.inderes.com/vimian-group/q3-report-2026

Related presentation materials will be available on Vimian’s website (https://vimian.com/investors/reports-and-presentations/) ahead of the telephone and web conference.